Pharmathene, Inc. (f/k/a PIP)

[surf1944]

8:08AM PharmAthene announced it has received notification from the FDA that its SparVax rPA anthrax vaccine program has been placed on clinical hold (PIP) 2.00 : Co announced it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.